Metabolic magnetic resonance imaging: A case for bioscales in medicine

Functional Neuroradiology: Principles and Clinical Applications

Volumn , Issue , 2012, Pages 911-928

  Thulborn, Keith R ^a   Atkinson, Ian C ^a   Lu, Aiming ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84865468720     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4419-0345-7_44     Document Type: Chapter

References (46)

1. Meek PD, McKeithan K, Schumock GT. Economic considerations in Alzheimer’s disease. Pharmacotherapy. 1998, 18(2 Pt 2):68-73. discussion 79-82.
2. Szekely CA, Breitner JC, Zandi PP Prevention of Alzheimer’s disease. Int Rev Psychiatry. 2007, 19(6):693-706.
3. Desikan RS, Cabral HJ, Hess CP, Dillon WP, Glastonbury CM, Weiner MW, et al. Automated MRI measures identify individuals with mild cognitive impairment and Alzheimer’s disease. Brain. 2009, 132(8):2048-57.
4. Boyle PA, Buchman AS, Wilson RS, Kelly JF, Bennett DA. The APOE 4 Allele is associated with incident mild cognitive impair-mentamongcommunity-dwellingolderpersons. Neuroepidemiology. 2010, 34:43-9.
5. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991, 82:239-59.
6. Braak H, Braak E, Bohl J. Staging of Alzheimer-related cortical destruction. Eur Neurol. 1993, 33:403-8.
7. Braak H, Braak E. Staging of Alzheimer’s disease-related neurofibrillary changes. Neurobiol Aging. 1995, 16:271-8.
8. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997, 18:351-7.
9. Thal DR, Rub U, Schultz C, et al. Sequence of Abeta-protein deposition in the human medial temporal lobe. J Neuropathol Exp Neurol. 2000, 59:733-48.
10. Braak H, Braak E, Bohl J, et al. Age, neurofibrillary changes, A beta-amyloid and the onset of Alzheimer’s disease. Neurosci Lett. 1996, 210:87-90.
11. Fjell AM, Walhovd KB, Fennema-Notestine C, McEvoy LK, Hagler DJ, Holland D, et al. Alzheimer’s Disease Neuroimaging Initiative. CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer’s disease. J Neurosci. 2010, 30(6):2088-101.
12. Snitz BE, O'Meara ES, Carlson MC, Arnold AM, Ives DG, Rapp SR, et al. Ginkgo biloba for preventing cognitive decline in older adults. A randomized trial. JAMA. 2009, 30(24):2663-70.
13. Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, et al. Effects of Tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer’s disease. JAMA. 2009, 302(23):2557-64.
14. Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA, Foster NL, Jack CR Jr., Galasko DR, Doody R, Kaye J, Sano M, Mohs R, Gauthier S, Kim HT, Jin S, Schultz AN, Schafer K, Mulnard R, van Dyck CH, Mintzer J, Zamrini EY, Cahn-Weiner D, Thal LJ, Alzheimer’s Disease Cooperative Study. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol. 2004, 61(1):59-66
15. DeCarli C, Frisoni GB, Clark CM, Harvey D, Grundman M, Petersen RC, Thal LJ, Jin S, Jack CR Jr., Scheltens P, Alzheimer’s Disease Cooperative Study Group. Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. Arch Neurol. 2007, 64(1):108-15
16. Fleisher A, Grundman M, Jack CR, Petersen RC, Taylor C, Kim HT, et al. Sex, apolipoprotein E epsilon 4 status, and hippocampal volume in mild cognitive impairment. Arch Neurol. 2005, 62(6): 953-7.
17. Fleisher AS, Sowell BB, Taylor C, Gamst AC, Petersen RC, Thal LJ, et al. Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology. 2007, 68(19):1588-95.
18. He J, Farias S, Martinez O, Reed B, Mungas D, Decarli C. Differences in brain volume, hippocampal volume, cerebrovascular risk factors, and apolipoprotein E4 among mild cognitive impairment subtypes. Arch Neurol. 2009, 66(11):1393-9.
19. Yushkevich PA, Avants BB, Das SR, Pluta J, Altinay M, the Alzheimer’s Disease Neuroimaging Initiative. Bias in estimation of hippocampal atrophy using deformation-based morphometry arises from asymmetric global normalization: an illustration in ADNI 3 T MRI data. Neuroimage. 2010, 50(2):434-45.
20. Thulborn KR, Lu A, Atkinson IC, Damen F, Villano JL. Quantitative sodium MR imaging and sodium bioscales for the management of brain tumors. Neuroimaging Clin N Am. 2009, 19:615-24.
21. Atkinson IC, Thulborn KR. Feasibility of mapping the tissue mass corrected bioscale of cerebral metabolic rate of oxygen consumption using 17-oxygen and 23-sodium MR imaging in a human brain at 9.4 T. Neuroimage. 2010, 51(2):723-33.
22. Hilal SK, Maudsley AA, Ra JB, Simon HE, Roschmann P, Wittekoek S, et al. In vivo NMR imaging of sodium-23 in the human head. J Comput Assist Tomogr. 1985, 9(1):1-7.
23. Thulborn KR, Ackerman JJH. Absolute molar concentrations by NMR in inhomogeneous B1: a scheme for analysis of in vivo metabolites. J Magn Reson. 1983, 55:357-71.
24. Boada F, Gillen J, Shen G, Chang S, Thulborn K. Fast three dimensional sodium imaging. Magn Reson Med. 1997, 37:706-15.
25. Lu A, Atkinson IC, Claiborne T, Damen FC, Thulborn KR. Quantitative sodium imaging with a flexible twisted projection pulse sequence. Magn Reson Med. 2010, 63(6):1583-93.
26. Gurney PT, Hargreaves BA, Nishimura DG. Design and analysis of a practical 3D cones trajectory. Magn Reson Med. 2006, 55:575-82.
27. Atkinson IC, Lu A, Thulborn KR. Characterization and correction of system delays and eddy currents for MR imaging with ultrashort echo-time and time-varying gradients. Magn Reson Med. 2009, 62(2):532-7.
28. Schomberg H. Off-resonance correction of MR images. IEEE Trans Med Imaging. 1999, 18:481-95.
29. Insko EK, Bolinger L. Mapping of the radiofrequency field. J Magn Reson A. 1993, 103:82-5.
30. Sykova Z, Nicholson C. Diffusion in brain extracellular space. Physiol Rev. 2008, 88:1277-340.
31. Neeb H, Ermer V, Stocker T, Shah NJ. Fast quantitative mapping of absolute water content with full brain coverage. Neuroimage. 2008, 42:1094-109.
32. Lu A, Brodsky E, Grist TM, Block WF. Rapid fat-suppressed isotropic steady-state free precession imaging using true 3D multiple-halfecho projection reconstruction. Magn Reson Med. 2005, 53:692-9. http://surfer.nmr.mgh.harvard.edu.
33. Mellon EA, Pilkinton DT, Clark CM, Elliott MA, Witschey II WR, Borthakur A, et al. Sodium MR imaging detection of mild Alzheimer disease: preliminary study. AJNR Am J Neuroradiol. 2009, 30(5):978-84.
34. Somjen GG. Ions of the Brain, Normal function, seizures and stroke. New York: Oxford University Press, 2004.
35. Eckert B. Acute stroke therapy 1981-2009. Klin Neuroradiol. 2009, 19(1):8-19.
36. Fagan SC, Morgenstern LB, Petitta A, Ward RE, Tilley BC, Marler JR, et al. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group. Neurology. 1998, 50(4):883-90.
37. Parsons MW, Christensen S, McElduff P, Levi CR, Butcher KS, De Silva DA, et al. Pretreatment diffusion- and perfusion-MR lesion volumes have a crucial influence on clinical response to stroke thrombolysis. J Cereb Blood Flow Metab. 2010, 30(6):1214-25.
38. Thulborn KR, Gindin TS, Davis D, Erb P. Comprehensive MRI protocol for stroke management: tissue sodium concentration as a measure of tissue viability in a non-human primate model and clinical studies. Radiology. 1999, 139:26-34.
39. Thulborn KR, Davis D, Snyder J, Yonas H, Kassam A. Sodium MR imaging of acute and subacute stroke for assessment of tissue viability. Neuroimaging Clin N Am. 2005, 15:639-53.
40. Shawl EG, Seiferheld W, Scott C, et al. Re-examining the radiation therapy oncology group (RTOG) recursive partitioning analysis (RPA) for glioblastoma multiforme (GBM) patients. Int J Radiat Oncol Biol Phys. 2003, 57(2):S135-6.
41. Barajas Jr. RF, Chang JS, Segal MR, Parsa AT, McDermott MW, Berger MS, et al. Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology. 2009, 253(2):486-96.
42. Hu LS, Baxter LC, Smith KA, Feuerstein BG, Karis JP, Eschbacher JM, et al. Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements. AJNR Am J Neuroradiol. 2009, 30(3):552-8.
43. 23Na MRI accurately measures fixed charge density in articular cartilage. Magn Reson Med. 2002, 47(2):284-91.
44. Maril N, Rosen Y, Reynolds GH, Ivanishev A, Ngo L, Lenkinsk RE. Sodium MRI of the human kidney at 3 Tesla. Magn Reson Med. 2006, 56(6):1229-34.
45. 2delivery system. Neuroimage. 2004, 22(2):611-8.
46. Go KG. Physical and biochemical methods for analysis of fluid compartments. In: Boulton AA, Baker GB, Walz W, editors. Neuromethods 9: neuronal microenvironment. Clifton: Humana Press, 1998. p. 127-85.